<DOC>
	<DOCNO>NCT02914938</DOCNO>
	<brief_summary>The purpose study determine minimum biologically effective dose ME-401 ; determine maximally tolerate dose ME-401 determine dose limit toxicity ME-401 . Secondary objective evaluate safety profile efficacy ME-401 .</brief_summary>
	<brief_title>Study ME-401 Subjects With Relapsed/Refractory CLL/SLL FL</brief_title>
	<detailed_description>This Phase 1b , open-label , dose escalation/expansion study seven plan dose level ( Cohorts ) ME-401 . DLT assess within first 56 day ( 8 week ) . A Continual Reassessment Method ( CRM ) model use determine dose escalation/de-escalation . Dose level consist 6 subject expand enroll 12 subject . The total number cohort depend incidence DLTs .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Diagnosis relapsed/refractory CLL and/or relapsed/refractory SLL FL No prior therapy PI3Kd inhibitor No prior therapy Bruton tyrosine kinase ( BTK ) inhibitor unless subject intolerant BTK therapy QTinterval correct accord Fridericia 's formula ( QTcF ) â‰¤ 450 millisecond ( m ) For female childbearing potential , negative serum pregnancy test within 14 day study Day 0 Known histological transformation CLL aggressive lymphoma Uncontrolled autoimmune hemolytic anemia immune thrombocytopenia Subjects test positive hepatitis B surface antigen and/or hepatitis B core antibody Positive hepatitis C virus antibody ( HCV Ab ) human immunodeficiency virus ( HIV ) antibody Ongoing druginduced pneumonitis History clinically significant cardiovascular abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>